United-Guardian (UG) Q2 2024 earnings summary

Executive summary

• Net sales for Q2 2024 increased 28% year-over-year to $3.39M; first half 2024 sales rose 27% to $6.65M.

• Net income for Q2 2024 was $956K, up from $461K in Q2 2023; first half net income was $1.88M, up from $1.22M.

• Growth driven by strong demand for cosmetic ingredients, especially in China, and higher medical lubricant sales.

• Industrial product line discontinued after Q2 2023; new sexual wellness product line expected to launch in H2 2024.

• Renacidin production resumed in late March after a contract manufacturer shutdown; sales are recovering.

Financial highlights

• Gross margin improved as cost of sales fell to 46% of sales in Q2 2024 from 54% in Q2 2023.

• Operating expenses rose 5% year-over-year in Q2 2024, mainly due to higher board fees and payroll.

• Investment income nearly doubled year-over-year in Q2 2024, reflecting a shift to U.S. Treasury Bills.

• Net loss on marketable securities of $9.5K in Q2 2024 versus a $7.5K gain in Q2 2023.

• Q2 2024 operating income: $1.11M, up from $518K in Q2 2023.

Outlook and guidance

• Management expects working capital to be sufficient for at least the next 12 months.

• Anticipates continued dividend payments, investment in marketable securities, and organic growth.

• New Natrajel® sexual wellness line to begin sales in H2 2024.

• Forward-looking statements caution about risks and uncertainties affecting future performance.